Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results
Globe Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤COVID-19 trial topline data from approximately 5,400 participants expected by mid-year 2027
- ➤$278.0 million cumulative BARDA contract cash received as of September 30, 2026
- ➤Cash, equivalents, and short-term investments totaled $65.5 million; runway anticipated into Q2 2027
- ➤Q3 revenue $10.6 million, down from $72.4 million year over year
- ➤Q3 net loss widened to $17.7 million from $8.1 million year over year
Expert Statements
Steven Lo, Chief Executive Officer of Vaxart
“During the third quarter, the Vaxart team worked diligently to advance our Phase 2b COVID-19 trial.”
Steven Lo, Chief Executive Officer of Vaxart
“The release of the topline efficacy and safety data from the main cohort remains a top priority, and we continue to actively work toward completion of analytical testing and disclosure of the trial results, in collaboration with our partner BARDA.”
Steven Lo, Chief Executive Officer of Vaxart
“In parallel, we continue to reinforce our competitive positioning, recently expanding our global intellectual property portfolio with a key European patent protecting our oral recombinant norovirus vaccine candidate and derivatives thereof.”
Steven Lo, Chief Executive Officer of Vaxart
“Beyond our clinical work, we remain focused on expanding board governance and fostering open dialogue with our retail stockholders as highlighted by the addition of Dr. Raquel Bono to our Board as Chair of our newly established Stockholder Engagement Committee.”
Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027
Expanded intellectual property portfolio with new European patent that further protects core IP for Vaxart's oral recombinant norovirus vaccine candidate
Get started
Create a free account to read the full story.